Biohyalux's Performance Forecast for 2025: Reshaping Long-term Competitiveness through "Quality Growth"
On January 30th, Bloomage Biotechnology Corporation Limited released an announcement on the pre - increase of its annual performance for 2025. The announcement shows that the company expects its net profit attributable to the owners of the parent company to reach between 270 million yuan and 320 million yuan in 2025, a year - on - year increase of 54.93% to 83.63%; the net profit after deducting non - recurring gains and losses is expected to be between 167 million yuan and 217 million yuan, a year - on - year increase of 55.68% to 102.29%. The company's profitability has been significantly improved, reflecting the development achievements of continuous improvement in business quality.
Bloomage Biotechnology stated that the core driving force for this performance growth does not come from short - term scale expansion, but from the systematic transformation and upgrading that has been continuously promoted in recent years. The company is gradually completing the strategic transformation from "scale - oriented" to "quality - oriented" and "efficiency - oriented", promoting a deep - seated reconstruction of its business model.
At the organizational management level, Bloomage Biotechnology integrated departments with overlapping functions, optimized the hierarchical settings, promoted the upgrading of the organization towards flatness and agility, improved decision - making efficiency, and effectively reduced operating costs. In 2025, the management expenses decreased by more than 10% year - on - year. The effective control of costs and expenses provided basic support for profit growth.
At the business operation level, Bloomage Biotechnology focused on professional development directions and continuously optimized its business structure and resource allocation. By strengthening the collaborative management of the supply chain and promoting the optimization of the inventory structure, it invested more resources in core areas with long - term competitive advantages and continuously improved its profitability against the backdrop of pressured revenues. In 2025, the sales expenses decreased by more than 30% year - on - year, and the profitability continued to improve despite the pressured revenues.
At the R & D and technological innovation level, based on the key role of carbohydrate substances in cell differentiation and signaling mechanisms, Bloomage Biotechnology focused on three core R & D directions: extracellular matrix, inter - cellular communication, and intracellular. It strengthened the coordinated promotion of basic research and applied research, and relying on the underlying technology of synthetic biology and the world's largest pilot - scale transformation platform, continuously improved the industrialization ability of bioactive substances and regenerative materials, and accelerated the transformation process of scientific research achievements into products and life - health solutions. Focusing on the key directions of anti - aging intervention and tissue regeneration, the company continuously promoted the layout of original technologies and product transformation, laying a solid scientific and technological foundation for medium - and long - term business development.
Meanwhile, Bloomage Biotechnology actively promoted the in - depth integration of artificial intelligence with business scenarios and continuously promoted intelligent upgrading in fields such as R & D, manufacturing, supply chain management, and financial operations. By strengthening the in - depth integration of AI technology with business, optimizing business processes and data governance, it improved the operational efficiency of the entire chain including production, supply chain, and management, which is expected to further promote the improvement of business quality.
The performance growth in 2025 is the comprehensive result of the coordinated efforts of Bloomage Biotechnology in organizational optimization, business focus, technological innovation, and digital empowerment. It is also a phased manifestation of the long - term commitment to high - quality development and core capability building. In the future, the company will continue to adhere to scientific and technological innovation as the core, supported by synthetic biology technology and industrialization platforms, continuously consolidate its long - term competitive advantages, and promote the steady improvement of business quality and sustainable development ability.